Vertex Pharma (VRTX.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Nov4

Vertex Pharma released FY2025 9 Months earnings on November 3 After-Market (EST), actual revenue USD 5.735 B, actual EPS USD 6.48

00:00

Vertex Pharma released FY2025 Q3 earnings on November 3 After-Market EST, actual revenue USD 3.076 B (forecast USD 3.059 B), actual EPS USD 4.2 (forecast USD 4.1053)

00:00

Oct27

Vertex Pharma to Release FY2025 Q3 Earnings on November 3 After-Market (EST), Forecast Revenue USD 3.059 B, EPS USD 4.11

00:08

Oct17

Vertex Pharmaceuticals Initiates Clinical Trial for Primary Membranous Nephropathy and Advances Biologics License Application for IgA Nephropathy

13:04

Oct13

Meacham Maintains Buy Rating on Vertex Pharmaceuticals with a Target Price of $488.86

10:58

Oct9

Vertex Pharmaceuticals Gets Buy Rating From Evercore ISI But RBC Capital Maintains Hold Rating

12:11

Schedules & Filings

Schedules

Filings

Nov3

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 3.076 B, Net Income 1.083 B, EPS 4.2

Aug4

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 2.965 B, Net Income 1.033 B, EPS 3.99

May5

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 2.77 B, Net Income 646.3 M, EPS 2.49

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More